25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

NGNE (Neurogene) Stock Analysis
Buy, Hold or Sell?

Let's analyze Neurogene together

I guess you are interested in Neurogene Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Neurogene’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Neurogene’s Price Targets

I'm going to help you getting a better view of Neurogene Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Neurogene Inc

I send you an email if I find something interesting about Neurogene Inc.

1. Quick Overview

1.1. Quick analysis of Neurogene (30 sec.)










1.2. What can you expect buying and holding a share of Neurogene? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$13.90
Expected worth in 1 year
$17.69
How sure are you?
29.4%

+ What do you gain per year?

Total Gains per Share
$3.79
Return On Investment
19.2%

For what price can you sell your share?

Current Price per Share
$19.75
Expected price per share
$6.875 - $25.35
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Neurogene (5 min.)




Live pricePrice per Share (EOD)
$19.75
Intrinsic Value Per Share
$-56.73 - $-67.12
Total Value Per Share
$-42.84 - $-53.22

2.2. Growth of Neurogene (5 min.)




Is Neurogene growing?

Current yearPrevious yearGrowGrow %
How rich?$291.7m$62.2m$161.4m72.2%

How much money is Neurogene making?

Current yearPrevious yearGrowGrow %
Making money-$20.2m-$12.2m-$8m-39.6%
Net Profit Margin-499.8%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Neurogene (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Neurogene?

Welcome investor! Neurogene's management wants to use your money to grow the business. In return you get a share of Neurogene.

First you should know what it really means to hold a share of Neurogene. And how you can make/lose money.

Speculation

The Price per Share of Neurogene is $19.75. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Neurogene.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Neurogene, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $13.90. Based on the TTM, the Book Value Change Per Share is $0.95 per quarter. Based on the YOY, the Book Value Change Per Share is $2.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Neurogene.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.08-5.5%-1.17-5.9%-0.62-3.2%-0.74-3.8%-0.55-2.8%-0.53-2.7%
Usd Book Value Change Per Share-7.00-35.4%0.954.8%2.1610.9%0.964.9%0.562.8%0.412.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-7.00-35.4%0.954.8%2.1610.9%0.964.9%0.562.8%0.412.1%
Usd Price Per Share11.71-28.23-18.77-15.90-13.45-11.95-
Price to Earnings Ratio-2.71--6.05--5.63--4.07--9.26--416.20-
Price-to-Total Gains Ratio-1.67--19.56--3.63--8.16--11.86--16.53-
Price to Book Ratio0.84-2.77-1.67-1.59-2.17-2.18-
Price-to-Total Gains Ratio-1.67--19.56--3.63--8.16--11.86--16.53-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share19.75
Number of shares50
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.950.56
Usd Total Gains Per Share0.950.56
Gains per Quarter (50 shares)47.4327.77
Gains per Year (50 shares)189.73111.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101901800111101
203793700222212
305695600333323
407597500444434
509499400555545
60113811300667656
70132813200778767
80151815100889878
901708170001000989
10018971890011111100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.033.00.02.9%1.033.00.02.9%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%10.024.00.029.4%10.024.00.029.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.034.00.0%0.00.034.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%7.013.00.035.0%10.024.00.029.4%10.024.00.029.4%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Neurogene Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---6.9970.949-838%2.159-424%0.962-828%0.555-1360%0.409-1812%
Book Value Per Share--13.89713.012+7%6.748+106%7.687+81%5.895+136%5.275+163%
Current Ratio--21.03015.785+33%11.000+91%12.623+67%15.632+35%17.423+21%
Debt To Asset Ratio--0.0750.113-34%0.981-92%0.421-82%0.297-75%0.205-64%
Debt To Equity Ratio--0.0810.129-38%0.133-39%0.155-48%0.143-44%0.117-31%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--514962520.770677710765.228-24%372645645.325+38%387592404.416+33%487160640.266+6%433097216.313+19%
Eps---1.079-1.169+8%-0.624-42%-0.742-31%-0.546-49%-0.529-51%
Ev To Ebitda Ratio---4.967-8.625+74%-6.832+38%-5.864+18%-13.536+173%-943.563+18896%
Free Cash Flow Per Share---1.027-1.0260%-0.918-11%-0.705-31%-0.508-50%-0.437-57%
Free Cash Flow To Equity Per Share---1.0262.180-147%0.598-272%0.869-218%0.508-302%0.351-392%
Gross Profit Margin--1.0001.011-1%1.361-27%1.212-17%1.132-12%1.078-7%
Intrinsic Value_10Y_max---67.120----------
Intrinsic Value_10Y_min---56.734----------
Intrinsic Value_1Y_max---3.389----------
Intrinsic Value_1Y_min---3.327----------
Intrinsic Value_3Y_max---12.726----------
Intrinsic Value_3Y_min---12.098----------
Intrinsic Value_5Y_max---25.129----------
Intrinsic Value_5Y_min---23.105----------
Market Cap281676475.000+13%245866520.770478328515.228-49%324892895.325-24%278281321.083-12%364728940.266-33%320137775.137-23%
Net Profit Margin----4.9980%-0%-1.6660%-1.0000%-0.5850%
Operating Margin----4.9970%-0%-1.6660%-0.9990%-0.5850%
Operating Ratio---9.947-100%-0%3.316-100%1.989-100%1.226-100%
Pb Ratio1.421+41%0.8432.773-70%1.673-50%1.589-47%2.170-61%2.176-61%
Pe Ratio-4.578-69%-2.714-6.049+123%-5.631+107%-4.075+50%-9.255+241%-416.203+15235%
Price Per Share19.750+41%11.71028.230-59%18.765-38%15.905-26%13.451-13%11.951-2%
Price To Free Cash Flow Ratio-4.810-69%-2.852-7.101+149%-5.453+91%-21.941+669%-24.450+757%-17.553+516%
Price To Total Gains Ratio-2.823-69%-1.674-19.560+1069%-3.628+117%-8.156+387%-11.865+609%-16.534+888%
Quick Ratio--36.54224.319+50%16.527+121%19.127+91%20.367+79%22.003+66%
Return On Assets---0.072-0.089+24%-0.092+28%-0.100+39%-0.089+23%-0.106+48%
Return On Equity---0.078-0.102+31%-0.061-22%-0.102+31%-0.094+21%-0.113+46%
Total Gains Per Share---6.9970.949-838%2.159-424%0.962-828%0.555-1360%0.409-1812%
Usd Book Value--291795000.000223649500.000+30%62206750.000+369%128455666.667+127%141779250.000+106%128060264.706+128%
Usd Book Value Change Per Share---6.9970.949-838%2.159-424%0.962-828%0.555-1360%0.409-1812%
Usd Book Value Per Share--13.89713.012+7%6.748+106%7.687+81%5.895+136%5.275+163%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--514962520.770677710765.228-24%372645645.325+38%387592404.416+33%487160640.266+6%433097216.313+19%
Usd Eps---1.079-1.169+8%-0.624-42%-0.742-31%-0.546-49%-0.529-51%
Usd Free Cash Flow---21554000.000-17812500.000-17%-14884437.635-31%-13785141.045-36%-12577100.027-42%-10736729.134-50%
Usd Free Cash Flow Per Share---1.027-1.0260%-0.918-11%-0.705-31%-0.508-50%-0.437-57%
Usd Free Cash Flow To Equity Per Share---1.0262.180-147%0.598-272%0.869-218%0.508-302%0.351-392%
Usd Market Cap281676475.000+13%245866520.770478328515.228-49%324892895.325-24%278281321.083-12%364728940.266-33%320137775.137-23%
Usd Price Per Share19.750+41%11.71028.230-59%18.765-38%15.905-26%13.451-13%11.951-2%
Usd Profit---22647000.000-20217500.000-11%-12202250.000-46%-15463666.667-32%-14312100.000-37%-13625764.706-40%
Usd Revenue---231250.000-100%-0%77083.333-100%46250.000-100%762500.000-100%
Usd Total Gains Per Share---6.9970.949-838%2.159-424%0.962-828%0.555-1360%0.409-1812%
 EOD+5 -3MRQTTM+16 -19YOY+14 -193Y+16 -195Y+16 -1910Y+16 -19

3.3 Fundamental Score

Let's check the fundamental score of Neurogene Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.578
Price to Book Ratio (EOD)Between0-11.421
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than136.542
Current Ratio (MRQ)Greater than121.030
Debt to Asset Ratio (MRQ)Less than10.075
Debt to Equity Ratio (MRQ)Less than10.081
Return on Equity (MRQ)Greater than0.15-0.078
Return on Assets (MRQ)Greater than0.05-0.072
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Neurogene Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.488
Ma 20Greater thanMa 5019.018
Ma 50Greater thanMa 10017.451
Ma 100Greater thanMa 20016.120
OpenGreater thanClose19.250
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Neurogene Inc

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Fundamental data was last updated by Penke on 2025-06-29 15:24:02.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Neurogene earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Neurogene to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Neurogene Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-499.8%+499.8%
TTM-499.8%YOY--499.8%
TTM-499.8%5Y-100.0%-399.8%
5Y-100.0%10Y-58.5%-41.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--92.7%+92.7%
TTM-499.8%-141.4%-358.4%
YOY--186.1%+186.1%
3Y-166.6%-248.3%+81.7%
5Y-100.0%-338.6%+238.6%
10Y-58.5%-488.9%+430.4%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Neurogene is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Neurogene to theΒ Biotechnology industry mean.
  • -7.2% Return on Assets means thatΒ Neurogene generatedΒ $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Neurogene Inc:

  • The MRQ is -7.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -8.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.2%TTM-8.9%+1.7%
TTM-8.9%YOY-9.2%+0.3%
TTM-8.9%5Y-8.9%0.0%
5Y-8.9%10Y-10.6%+1.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.2%-11.5%+4.3%
TTM-8.9%-11.6%+2.7%
YOY-9.2%-11.4%+2.2%
3Y-10.0%-11.8%+1.8%
5Y-8.9%-12.1%+3.2%
10Y-10.6%-13.8%+3.2%
4.3.1.3. Return on Equity

Shows how efficient Neurogene is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Neurogene to theΒ Biotechnology industry mean.
  • -7.8% Return on Equity means Neurogene generated $-0.08Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Neurogene Inc:

  • The MRQ is -7.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -10.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.8%TTM-10.2%+2.4%
TTM-10.2%YOY-6.1%-4.1%
TTM-10.2%5Y-9.4%-0.8%
5Y-9.4%10Y-11.3%+2.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.8%-13.6%+5.8%
TTM-10.2%-14.9%+4.7%
YOY-6.1%-14.4%+8.3%
3Y-10.2%-17.0%+6.8%
5Y-9.4%-17.9%+8.5%
10Y-11.3%-20.1%+8.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Neurogene Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Neurogene is operatingΒ .

  • Measures how much profit Neurogene makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Neurogene to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Neurogene Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-499.7%+499.7%
TTM-499.7%YOY--499.7%
TTM-499.7%5Y-99.9%-399.7%
5Y-99.9%10Y-58.5%-41.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--229.2%+229.2%
TTM-499.7%-250.3%-249.4%
YOY--205.1%+205.1%
3Y-166.6%-220.2%+53.6%
5Y-99.9%-342.6%+242.7%
10Y-58.5%-475.5%+417.0%
4.3.2.2. Operating Ratio

Measures how efficient Neurogene is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Neurogene Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM9.947-9.947
TTM9.947YOY-+9.947
TTM9.9475Y1.989+7.957
5Y1.98910Y1.226+0.763
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.110-2.110
TTM9.9472.704+7.243
YOY-3.063-3.063
3Y3.3163.576-0.260
5Y1.9894.713-2.724
10Y1.2266.512-5.286
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Neurogene Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Neurogene is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 21.03Β means the company has $21.03 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Neurogene Inc:

  • The MRQ is 21.030. The company is very able to pay all its short-term debts. +2
  • The TTM is 15.785. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ21.030TTM15.785+5.245
TTM15.785YOY11.000+4.785
TTM15.7855Y15.632+0.153
5Y15.63210Y17.423-1.792
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.0303.661+17.369
TTM15.7853.786+11.999
YOY11.0004.121+6.879
3Y12.6234.680+7.943
5Y15.6325.765+9.867
10Y17.4236.150+11.273
4.4.3.2. Quick Ratio

Measures if Neurogene is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Neurogene to theΒ Biotechnology industry mean.
  • A Quick Ratio of 36.54Β means the company can pay off $36.54 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Neurogene Inc:

  • The MRQ is 36.542. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 24.319. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ36.542TTM24.319+12.224
TTM24.319YOY16.527+7.791
TTM24.3195Y20.367+3.951
5Y20.36710Y22.003-1.635
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ36.5422.826+33.716
TTM24.3193.128+21.191
YOY16.5273.782+12.745
3Y19.1274.304+14.823
5Y20.3675.703+14.664
10Y22.0036.454+15.549
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Neurogene Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of NeurogeneΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Neurogene to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.07Β means that Neurogene assets areΒ financed with 7.5% credit (debt) and the remaining percentage (100% - 7.5%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Neurogene Inc:

  • The MRQ is 0.075. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.113. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.075TTM0.113-0.038
TTM0.113YOY0.981-0.869
TTM0.1135Y0.297-0.184
5Y0.29710Y0.205+0.092
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0750.324-0.249
TTM0.1130.347-0.234
YOY0.9810.327+0.654
3Y0.4210.339+0.082
5Y0.2970.349-0.052
10Y0.2050.382-0.177
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Neurogene is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Neurogene to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 8.1% means that company has $0.08 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Neurogene Inc:

  • The MRQ is 0.081. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.129. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.081TTM0.129-0.049
TTM0.129YOY0.133-0.004
TTM0.1295Y0.143-0.014
5Y0.14310Y0.117+0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0810.383-0.302
TTM0.1290.436-0.307
YOY0.1330.410-0.277
3Y0.1550.446-0.291
5Y0.1430.460-0.317
10Y0.1170.509-0.392
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Neurogene generates.

  • Above 15 is considered overpriced butΒ always compareΒ Neurogene to theΒ Biotechnology industry mean.
  • A PE ratio of -2.71 means the investor is paying $-2.71Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Neurogene Inc:

  • The EOD is -4.578. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.714. Based on the earnings, the company is expensive. -2
  • The TTM is -6.049. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.578MRQ-2.714-1.863
MRQ-2.714TTM-6.049+3.335
TTM-6.049YOY-5.631-0.418
TTM-6.0495Y-9.255+3.206
5Y-9.25510Y-416.203+406.948
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.578-2.197-2.381
MRQ-2.714-2.027-0.687
TTM-6.049-2.527-3.522
YOY-5.631-3.733-1.898
3Y-4.075-3.717-0.358
5Y-9.255-6.036-3.219
10Y-416.203-6.649-409.554
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Neurogene Inc:

  • The EOD is -4.810. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.852. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -7.101. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.810MRQ-2.852-1.958
MRQ-2.852TTM-7.101+4.249
TTM-7.101YOY-5.453-1.647
TTM-7.1015Y-24.450+17.350
5Y-24.45010Y-17.553-6.897
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.810-3.007-1.803
MRQ-2.852-2.704-0.148
TTM-7.101-3.627-3.474
YOY-5.453-4.334-1.119
3Y-21.941-5.070-16.871
5Y-24.450-8.532-15.918
10Y-17.553-9.305-8.248
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Neurogene is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 0.84 means the investor is paying $0.84Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Neurogene Inc:

  • The EOD is 1.421. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.843. Based on the equity, the company is cheap. +2
  • The TTM is 2.773. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.421MRQ0.843+0.579
MRQ0.843TTM2.773-1.930
TTM2.773YOY1.673+1.100
TTM2.7735Y2.170+0.602
5Y2.17010Y2.176-0.006
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4211.921-0.500
MRQ0.8431.843-1.000
TTM2.7732.113+0.660
YOY1.6732.467-0.794
3Y1.5892.541-0.952
5Y2.1703.666-1.496
10Y2.1764.311-2.135
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Neurogene Inc.

4.8.3. Insider Transactions

Insiders are holding 9.279% of the shares of Neurogene Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-05-14Stuart CobbSELL679715.15
2025-03-13Christine Mikail CvijicSELL450116.94
2024-11-26Samsara Biocapital Gp, LlcBUY4877025.83
2024-11-22Christine Mikail CvijicBUY2400020.48
2024-11-22Rachel McminnBUY4750020.4
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets315,301
Total Liabilities23,506
Total Stockholder Equity291,795
 As reported
Total Liabilities 23,506
Total Stockholder Equity+ 291,795
Total Assets = 315,301

Assets

Total Assets315,301
Total Current Assets296,398
Long-term Assets18,903
Total Current Assets
Cash And Cash Equivalents 70,771
Short-term Investments 221,831
Net Receivables 596
Other Current Assets 3,200
Total Current Assets  (as reported)296,398
Total Current Assets  (calculated)296,398
+/-0
Long-term Assets
Property Plant Equipment 17,668
Long-term Assets Other 1,235
Long-term Assets  (as reported)18,903
Long-term Assets  (calculated)18,903
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,094
Long-term Liabilities9,412
Total Stockholder Equity291,795
Total Current Liabilities
Short-term Debt 4,182
Accounts payable 3,063
Other Current Liabilities 6,849
Total Current Liabilities  (as reported)14,094
Total Current Liabilities  (calculated)14,094
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt9,361
Long-term Liabilities Other 51
Long-term Liabilities  (as reported)9,412
Long-term Liabilities  (calculated)9,412
+/-0
Total Stockholder Equity
Retained Earnings -284,945
Other Stockholders Equity 576,740
Total Stockholder Equity (as reported)291,795
Total Stockholder Equity (calculated)291,795
+/-0
Other
Cash and Short Term Investments 292,602
Common Stock Shares Outstanding 20,996
Liabilities and Stockholders Equity 315,301
Net Debt -57,228
Net Invested Capital 291,795
Net Working Capital 282,304
Property Plant and Equipment Gross 29,587
Short Long Term Debt Total 13,543



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-30
> Total Assets 
164,069
154,380
143,329
133,284
121,602
110,329
95,623
104,426
87,814
77,618
75,434
73,743
69,791
147,023
153,051
145,324
221,690
210,519
200,103
187,023
175,934
163,263
149,126
137,021
126,576
115,948
98,460
74,011
89,586
222,573
195,350
179,823
164,120
335,730
315,301
315,301335,730164,120179,823195,350222,57389,58674,01198,460115,948126,576137,021149,126163,263175,934187,023200,103210,519221,690145,324153,051147,02369,79173,74375,43477,61887,814104,42695,623110,329121,602133,284143,329154,380164,069
   > Total Current Assets 
146,612
103,485
122,436
132,192
120,573
108,825
94,223
103,241
87,293
77,165
74,831
73,209
67,582
143,596
139,653
130,997
206,589
194,522
181,306
167,496
156,498
143,989
130,365
118,485
108,857
99,134
85,636
49,131
79,893
200,348
174,141
159,149
143,647
315,923
296,398
296,398315,923143,647159,149174,141200,34879,89349,13185,63699,134108,857118,485130,365143,989156,498167,496181,306194,522206,589130,997139,653143,59667,58273,20974,83177,16587,293103,24194,223108,825120,573132,192122,436103,485146,612
       Cash And Cash Equivalents 
86,225
32,301
20,916
27,147
47,105
52,032
66,610
99,130
86,731
76,928
74,169
72,700
66,306
143,093
139,417
130,474
202,028
192,556
179,269
165,113
155,802
142,467
128,057
77,526
40,335
37,887
35,494
45,563
25,226
148,210
150,140
111,032
66,633
136,586
70,771
70,771136,58666,633111,032150,140148,21025,22645,56335,49437,88740,33577,526128,057142,467155,802165,113179,269192,556202,028130,474139,417143,09366,30672,70074,16976,92886,73199,13066,61052,03247,10527,14720,91632,30186,225
       Short-term Investments 
59,711
70,758
100,665
104,130
72,590
56,053
26,050
3,007
0
0
0
0
0
0
0
0
0
0
0
0
0
0
141,088
38,931
66,543
58,497
47,942
53,281
53,281
48,947
19,393
42,873
72,360
175,819
221,831
221,831175,81972,36042,87319,39348,94753,28153,28147,94258,49766,54338,931141,088000000000000003,00726,05056,05372,590104,130100,66570,75859,711
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
577
577
0
600
589
647
0
648
596
5966480647589600057757700000000000000000000000000
       Other Current Assets 
676
426
855
915
878
740
1,563
1,104
562
237
662
509
1,276
503
236
523
4,561
1,966
2,037
2,383
696
1,522
2,308
2,028
1,979
3,828
2,200
986
3,568
3,191
4,608
5,244
4,654
2,870
3,200
3,2002,8704,6545,2444,6083,1913,5689862,2003,8281,9792,0282,3081,5226962,3832,0371,9664,5615232365031,2765096622375621,1041,563740878915855426676
   > Long-term Assets 
17,457
50,895
20,893
1,092
1,029
1,504
1,400
1,185
521
453
603
534
2,209
3,427
13,398
14,327
15,101
15,997
18,797
19,527
19,436
19,274
18,761
18,536
17,719
16,814
12,824
24,880
9,693
22,225
21,209
20,674
20,473
19,807
18,903
18,90319,80720,47320,67421,20922,2259,69324,88012,82416,81417,71918,53618,76119,27419,43619,52718,79715,99715,10114,32713,3983,4272,2095346034535211,1851,4001,5041,0291,09220,89350,89517,457
       Property Plant Equipment 
791
849
885
1,092
1,029
905
849
781
467
400
359
504
1,558
2,830
12,350
12,736
13,701
13,724
16,583
17,357
17,265
17,218
16,743
16,498
15,807
15,878
11,919
21,715
9,169
20,953
20,127
19,541
19,345
18,493
17,668
17,66818,49319,34519,54120,12720,9539,16921,71511,91915,87815,80716,49816,74317,21817,26517,35716,58313,72413,70112,73612,3502,8301,5585043594004677818499051,0291,092885849791
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
622
567
513
458
403
347
293
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000293347403458513567622000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-714
0
0-714000000000000000000000000000000000
> Total Liabilities 
8,706
9,716
6,386
8,676
7,510
11,442
9,798
13,749
11,092
4,946
3,892
1,414
2,916
5,336
15,931
16,625
21,350
19,303
21,135
19,952
21,068
20,399
19,033
20,313
20,929
21,617
17,103
257,220
14,351
36,549
24,573
24,809
26,706
25,355
23,506
23,50625,35526,70624,80924,57336,54914,351257,22017,10321,61720,92920,31319,03320,39921,06819,95221,13519,30321,35016,62515,9315,3362,9161,4143,8924,94611,09213,7499,79811,4427,5108,6766,3869,7168,706
   > Total Current Liabilities 
8,564
9,519
5,824
8,128
6,997
10,956
9,355
13,348
10,749
4,627
3,596
1,159
2,565
4,743
5,603
6,320
9,892
7,889
8,407
7,584
8,996
8,636
7,596
9,271
10,237
11,062
7,156
9,422
5,212
22,973
11,818
13,073
15,800
15,157
14,094
14,09415,15715,80013,07311,81822,9735,2129,4227,15611,06210,2379,2717,5968,6368,9967,5848,4077,8899,8926,3205,6034,7432,5651,1593,5964,62710,74913,3489,35510,9566,9978,1285,8249,5198,564
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
201
265
618
600
306
370
708
1,099
1,177
1,222
1,221
1,271
1,385
1,379
702
1,735
1,554
781
2,601
2,713
5,634
2,910
4,090
4,182
4,1824,0902,9105,6342,7132,6017811,5541,7357021,3791,3851,2711,2211,2221,1771,09970837030660061826520100000000000
       Accounts payable 
0
0
0
0
0
0
0
13,348
10,749
4,627
3,396
958
2,300
1,604
0
0
0
1,323
0
0
0
526
0
0
9,547
625
1,529
2,134
2,134
2,596
1,522
1,724
1,684
1,336
3,063
3,0631,3361,6841,7241,5222,5962,1342,1341,5296259,547005260001,3230001,6042,3009583,3964,62710,74913,3480000000
       Other Current Liabilities 
8,564
9,519
5,824
8,128
6,997
10,956
9,355
0
0
0
200
0
0
2,521
5,003
6,014
9,522
5,858
7,308
6,407
7,774
6,889
6,325
7,886
8,858
9,735
5,421
1,230
2,297
17,776
7,583
5,715
11,206
9,731
6,849
6,8499,73111,2065,7157,58317,7762,2971,2305,4219,7358,8587,8866,3256,8897,7746,4077,3085,8589,5226,0145,0032,521002000009,35510,9566,9978,1285,8249,5198,564
   > Long-term Liabilities 
142
197
562
548
513
486
443
401
343
319
296
255
351
593
10,328
10,305
11,458
11,414
12,728
12,368
12,072
11,763
11,437
11,042
10,692
10,555
9,947
247,798
9,139
13,576
12,755
11,736
10,906
10,198
9,412
9,41210,19810,90611,73612,75513,5769,139247,7989,94710,55510,69211,04211,43711,76312,07212,36812,72811,41411,45810,30510,328593351255296319343401443486513548562197142
> Total Stockholder Equity
155,363
144,664
136,943
124,608
114,092
98,887
85,825
90,677
76,722
72,672
71,542
72,329
66,875
141,687
137,120
128,699
200,340
191,216
178,968
167,071
154,866
142,864
130,093
116,708
105,647
94,331
81,357
-183,209
75,235
186,024
170,777
155,014
137,414
310,375
291,795
291,795310,375137,414155,014170,777186,02475,235-183,20981,35794,331105,647116,708130,093142,864154,866167,071178,968191,216200,340128,699137,120141,68766,87572,32971,54272,67276,72290,67785,82598,887114,092124,608136,943144,664155,363
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
0
170,777
0
0
0
0
0000170,777010100000000000000000000000000
   Retained Earnings -284,945-262,298-242,784-222,567-204,075-187,154-471,870-189,537-465,259-451,055-437,609-424,537-408,849-393,498-378,331-362,885-347,756-332,806-320,166-317,917-308,171-299,529-291,428-232,296-232,295-230,087-225,200-210,207-213,125-198,502-182,234-170,401-156,635-148,278-137,034
   Accumulated Other Comprehensive Income 
-8
-169
-205
-205
-103
-70
-24
-2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-91,875
-72
-92
-21
18
-244
-244
0
0
0
0
0
0
000000-244-24418-21-92-72-91,87500000000000000-2-24-70-103-205-205-169-8
   Capital Surplus 00000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000
   Other Stockholders Equity 
292,405
293,111
293,783
295,214
296,429
297,459
298,974
300,886
301,922
302,759
303,837
304,625
358,303
441,216
445,291
446,616
520,506
524,022
526,724
529,956
533,197
536,362
452,910
541,317
543,348
301,041
302,232
547,105
302,982
373,178
374,852
377,581
380,198
572,673
576,740
576,740572,673380,198377,581374,852373,178302,982547,105302,232301,041543,348541,317452,910536,362533,197529,956526,724524,022520,506446,616445,291441,216358,303304,625303,837302,759301,922300,886298,974297,459296,429295,214293,783293,111292,405



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue925
Cost of Revenue-3,247
Gross Profit-2,322-2,322
 
Operating Income (+$)
Gross Profit-2,322
Operating Expense-83,530
Operating Income-82,605-85,852
 
Operating Expense (+$)
Research Development60,917
Selling General Administrative22,613
Selling And Marketing Expenses0
Operating Expense83,53083,530
 
Net Interest Income (+$)
Interest Income8,467
Interest Expense-12
Other Finance Cost-0
Net Interest Income8,455
 
Pretax Income (+$)
Operating Income-82,605
Net Interest Income8,455
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-75,144-90,066
EBIT - interestExpense = -75,144
-75,144
-75,132
Interest Expense12
Earnings Before Interest and Taxes (EBIT)-75,132-75,132
Earnings Before Interest and Taxes (EBITDA)-71,885
 
After tax Income (+$)
Income Before Tax-75,144
Tax Provision-0
Net Income From Continuing Ops-75,144-75,144
Net Income-75,144
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses83,530
Total Other Income/Expenses Net7,461-8,455
 

Technical Analysis of Neurogene
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Neurogene. The general trend of Neurogene is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Neurogene's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Neurogene Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Neurogene Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 24.84 < 25.19 < 25.35.

The bearish price targets are: 11.77 > 6.875.

Know someone who trades $NGNE? Share this with them.πŸ‘‡

Neurogene Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Neurogene Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Neurogene Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Neurogene Inc. The current macd is -0.07555975.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Neurogene price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Neurogene. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Neurogene price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Neurogene Inc Daily Moving Average Convergence/Divergence (MACD) ChartNeurogene Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Neurogene Inc. The current adx is 22.83.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Neurogene shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Neurogene Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Neurogene Inc. The current sar is 14.65.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Neurogene Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Neurogene Inc. The current rsi is 56.49. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Neurogene Inc Daily Relative Strength Index (RSI) ChartNeurogene Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Neurogene Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Neurogene price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Neurogene Inc Daily Stochastic Oscillator ChartNeurogene Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Neurogene Inc. The current cci is 30.98.

Neurogene Inc Daily Commodity Channel Index (CCI) ChartNeurogene Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Neurogene Inc. The current cmo is 20.14.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Neurogene Inc Daily Chande Momentum Oscillator (CMO) ChartNeurogene Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Neurogene Inc. The current willr is -28.11839323.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Neurogene is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Neurogene Inc Daily Williams %R ChartNeurogene Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Neurogene Inc.

Neurogene Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Neurogene Inc. The current atr is 2.06398706.

Neurogene Inc Daily Average True Range (ATR) ChartNeurogene Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Neurogene Inc. The current obv is -3,506,157.

Neurogene Inc Daily On-Balance Volume (OBV) ChartNeurogene Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Neurogene Inc. The current mfi is 44.63.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Neurogene Inc Daily Money Flow Index (MFI) ChartNeurogene Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Neurogene Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-22ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-19BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Neurogene Inc Daily Candlestick Chart
DateCandlestick Pattern
2025-07-01Bearish Three Line Strike Candle Pattern

6.4. Technical Score

Let's check the technical score of Neurogene Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.488
Ma 20Greater thanMa 5019.018
Ma 50Greater thanMa 10017.451
Ma 100Greater thanMa 20016.120
OpenGreater thanClose19.250
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Neurogene with someone you think should read this too:
  • Are you bullish or bearish on Neurogene? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Neurogene? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Neurogene Inc

I send you an email if I find something interesting about Neurogene Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Neurogene Inc.

Receive notifications about Neurogene Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.